Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

485
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
485
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

437
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
437
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.3K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.3K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

821
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
821
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

757
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
757
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

1.4K
Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integration of functional immunomonitoring assays with PET/CT scans in TB patients identifies on-treatment biomarkers.

bioRxiv : the preprint server for biology·2026
Same author

Synthesis of 4-Aminoindole-Containing Cephalosporin Prodrugs and Their Biological Activity against <i>Mycobacterium tuberculosis</i>.

ACS infectious diseases·2026
Same author

<i>In vitro</i> dormancy models improve ability to predict treatment response in severe marmoset tuberculosis lesions.

bioRxiv : the preprint server for biology·2026
Same author

Identification and Evaluation of Dibasic Piperidines as Cell Wall Inhibitors against <i>Mycobacterium tuberculosis</i>.

ACS infectious diseases·2026
Same author

The Impacts of Pregnancy on Cognition and Cell Proliferation in a Live-Bearing Fish (Poeciliopsis gracilis).

The European journal of neuroscience·2026
Same author

PET-CT benchmarked detection and 5-year progression of asymptomatic tuberculosis: a longitudinal, prospective cohort study.

The Lancet. Respiratory medicine·2026

Related Experiment Video

Updated: Dec 27, 2025

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.2K

Current and future treatments for tuberculosis.

Anthony Lee1,2, Yingda Linda Xie2,3, Clifton E Barry2

  • 1Medical Research Scholars Program, National Institutes of Health, Bethesda, MD, USA.

BMJ (Clinical Research Ed.)
|March 4, 2020
PubMed
Summary

New clinical trials are poised to revolutionize tuberculosis (TB) treatment, offering hope for drug-sensitive, drug-resistant, and latent TB infections. These advancements aim to reduce the global burden of TB, a leading infectious cause of death.

More Related Videos

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.2K
Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

19.2K

Related Experiment Videos

Last Updated: Dec 27, 2025

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.2K
An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.2K
Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates
10:04

Analysis of 18FDG PET/CT Imaging as a Tool for Studying Mycobacterium tuberculosis Infection and Treatment in Non-human Primates

Published on: September 5, 2017

19.2K

Area of Science:

  • Infectious Diseases
  • Clinical Trials
  • Public Health

Background:

  • Tuberculosis (TB) treatment guidelines have seen minimal changes over the last 35 years.
  • TB remains a significant global health threat, being the leading cause of death from a single infectious agent.

Purpose of the Study:

  • To highlight upcoming transformations in TB treatment protocols.
  • To discuss advancements in managing drug-sensitive TB, drug-resistant TB, and latent TB infection.
  • To emphasize the impact of ongoing clinical trials on global TB control.

Main Methods:

  • Evaluation of novel and repurposed agents for TB treatment.
  • Assessment of adjunctive host-directed therapies.
  • Review of novel treatment strategies and updated guidelines for HIV-TB co-infection.
  • Analysis of the shift towards genotypic drug resistance testing.

Main Results:

  • Clinical trials are exploring diverse therapeutic avenues, including new drugs and treatment strategies.
  • Genotypic testing has accelerated the speed and improved the efficiency of drug resistance detection.
  • Updated guidelines for HIV-TB co-infection are emerging.

Conclusions:

  • Upcoming changes in TB treatment are essential to address global health disparities.
  • Ongoing research and clinical trials are critical for reducing TB morbidity and mortality worldwide.
  • Innovations in treatment and diagnostics promise to transform TB care.